FDA-approved epilepsy drug may help reverse osteoarthritis damage

Yale researchers report that in preclinical studies, the FDA-approved epilepsy drug lacosamide appears to block a protein involved in both pain signaling and cartilage destruction, potentially helping damaged joints shift back toward repair. The findings are preclinical and not yet confirmed in humans.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.